Autres langues Caribou Biosciences, Inc.

Actions

CRBU

US1420381089

Temps réel estimé Cboe BZX Autres places de cotation 17:03:04 30/04/2024			Varia. 5j.	Varia. 1 janv.
3,695 ^USD	-2,25 %		-7,29 %	-35,60 %

05/04	Mise à jour sectorielle : Les actions du secteur de la santé sont en hausse avant la cloche de vendredi	MT
04/04	Caribou Biosciences obtient l'autorisation de la FDA pour la phase 1 des tests de la thérapie cellulaire CB-010 chez les patients atteints de lupus	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
Caribou Biosciences : CB-010 ANTLER Case Study iwCAR-T 2024	23/04
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15/04
Caribou Biosciences : CB-012 IND-enabling preclinical data AACR 2024	09/04
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	05/04
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	04/04
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04/04
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	04/04
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	25/03
50 valores para invertir en IA, salud, movilidad y energía	25/03
50 aandelen om te beleggen in KI, gezondheid, mobiliteit en energie	23/03
50 titoli per investire in AI, salute, mobilità ed energia	22/03
50 Top-Aktien für Investitionen in KI, Gesundheit, Mobilität und Energie	22/03
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	11/03
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	11/03
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting	05/03
Caribou Biosciences to Participate in Upcoming Investor Conferences	15/02
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024	07/01
Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer	07/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Caribou Biosciences, Inc.

Actions

CRBU

US1420381089

Autres langues

Filtres